Oncocross Therapeutics: "Zaqubo has minimal drug interaction when combined with hyperlipidemia drugs"
Predicted impact: Low
Shareholder meeting notices already issued in the last 14 days.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.